Press Release

Printer Friendly Version View printer-friendly version
<< Back
Lubrizol LifeSciences Adds Commercial Manufacturing Capacity at Particle Sciences

    Arc_Logo_USE_10mm 

The Lubrizol Corporation

29400 Lakeland Boulevard, Wickliffe, Ohio 44092-2298

Lubrizol LifeSciences Adds Commercial 
Manufacturing Capacity at Particle Sciences

CLEVELAND, April 19, 2016 - The Lubrizol Corporation's LifeSciences, the leading contract development and manufacturing organization (CDMO) for complex drug products, is adding commercial drug product manufacturing capacity at its Particle Sciences facility in Bethlehem, PA. The 18,000 square foot capacity will include both sterile and non-sterile space with complete lyophilization and filling operations.  Among other things, the facility will be tailored for nano-milling and other complex processes.    

"As part of our plans for continued growth in this market, we have accelerated the commercial expansion plans at Particle Sciences. The work has already begun, and we plan to be operational in early 2017 with some of the capacity already spoken for by clients with whom we are currently developing products," explains Mark Mitchnick, LifeSciences' chief medical officer and Particle Sciences' CEO.

Particle Sciences has developed special expertise in particulates and drug eluting devices.  Over the last several years it has taken multiple products into the clinic on behalf of its clients and has a busy 2016 schedule of clinical trial material production in place. 

"While the general contract manufacturing organization (CMO) industry has gone through considerable consolidation around standard dosage forms, LifeSciences has focused on complex processes such as nano-milling, high pressure homogenization, extrusion and micro-particle fabrication.  We are clearly the leader in these areas with significant technology and infrastructure advantages.  This current multi-million-dollar expansion further demonstrates our commitment and fills a gap in the global CMO space," Mitchnick adds.

Deb Langer, vice president and general manager of Lubrizol LifeSciences comments, "Along with  expansion at several of our medical device manufacturing facilities, the addition of commercial manufacturing at Particle Sciences keeps us right on track as we grow Lubrizol LifeSciences into the premier pharmaceutical CDMO.  Working closely with our clients, we leverage our deep material sciences expertise, global supply chain and operational excellence in the increasingly demanding pharmaceutical and medical device industries. We have penned multiple manufacturing and partnering agreements so far and look to enter into many more.   Our corporate strength affords us a unique ability to structure such relationships."

-  more  -

Particle Sciences is part of Lubrizol Advanced Materials Inc.               

About Particle Sciences
Particle Sciences, part of Lubrizol LifeSciences, is an integrated provider of drug development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Particle Sciences is FDA registered and DEA licensed. Through a full range of formulation, analytic and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com, email info@particlesciences.com, or contact us at (610) 861- 4701 for information.

About Lubrizol LifeSciences
Lubrizol LifeSciences links science to life. An in-depth understanding of functional polymer systems, combined with a portfolio of specialty materials, enables LifeSciences to deliver application-specific, quality solutions to the medical device and pharmaceutical industries. The combination of our polymer expertise, drug formulation development and quality contract manufacturing allows LifeSciences to offer our customers end-to-end solutions for success in the drug delivery market.

About The Lubrizol Corporation
The Lubrizol Corporation, a Berkshire Hathaway company, is a technology-driven global company that combines complex, specialty chemicals to optimize the quality, performance and value of customers' products while reducing their environmental impact. It produces and supplies technologies to customers in the global transportation, industrial and consumer markets. These technologies include lubricant additives for engine oils, driveline and other transportation-related fluids, industrial lubricants, as well as additives for gasoline and diesel fuel. In addition, Lubrizol makes ingredients and additives for home care and personal care products and specialty materials encompassing polymer and coatings technologies, along with polymer-based pharmaceutical and medical device solutions. Our products for the oilfield market include technologies for exploration, production and transportation.

With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world.  Founded in 1928, Lubrizol has approximately 9,000 employees worldwide. Revenues for 2015 were $7 billion. For more information, visit Lubrizol.com

Media Contact
Ben Patti
(216) 447-5827
www.lubrizol.com/LifeSciences
www.particlesciences.com

###


HUG#2003423